TDZD-8 - CAS:327036-89-5 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	TDZD-8
英文名称:	TDZD-8
别名:	4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
CAS No:	327036-89-5	分子式:	C₁₀H₁₀N₂O₂S	分子量:	222.26
CAS No:	327036-89-5
分子式:	C₁₀H₁₀N₂O₂S
分子量:	222.26
MDL:	MFCD04973552

安全技术说明书(PDF) MSDS(PDF) 点击下载技术规格说明书(PDF) 点击下载产品说明书(PDF)

T80005 TDZD-8 ≥98% (HPLC) (psaitong)

相关产品

GSK-3β inhibitor 12
CAS No：784170-07-6
TWS 119
CAS No：1507095-58-0
GSK-3抑制剂II
CAS No：478482-75-6
KY19382
CAS No：2226664-93-1
1-(7-甲氧基喹啉-4-基)-3-[6-(三氟甲基)吡啶-2-基]脲
CAS No：1384424-80-9
WAY-313201
CAS No：571904-77-3

包装规格：

5mg 25mg 100mg in glass bottle

溶解性：

溶于DMSO( >10 mg/mL )

产品描述：

基本信息

产品编号：	T80005
产品名称：	TDZD-8
CAS:	327036-89-5	储存条件	粉末	2-8℃	四年

分子式：	C10H10N2O2S		溶于液体	-80℃	6个月
分子量：	222.26			-20℃	1个月
化学名：	4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione
Solubility (25°C)：
体外:	DMSO	44.5mg/mL (200.21mM)
	Ethanol	44.5mg/mL (200.21mM)
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility:≥2.5mg/mL(11.25mM);Clear solution
	此方案可获得 ≥ 2.5 mg/mL (11.25 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
	2.请依序添加每种溶剂：10% DMSO→90%(20% SBE-β-CD in saline) Solubility:≥2.5mg/mL(11.25mM);Clear solution
	此方案可获得 ≥ 2.5 mg/mL (11.25 mM，饱和度未知) 的澄清溶液。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
	3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility:≥2.5mg/mL(11.25mM);Clear solution
	此方案可获得 ≥ 2.5 mg/mL (11.25 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	4.4992mL	22.4962mL	44.9924mL
5mM	0.8998mL	4.4992mL	8.9985mL
10mM	0.4499mL	2.2496mL	4.4992mL

生物活性

产品描述	一种选择性的GSK-3抑制剂。
靶点	GSK-3β 2μM (IC50)
体外研究	TDZD8 results in a significant decline of cellular ATP levels in PC-3 cells.TDZD8 (10μM) treatment also triggers a drastic autophagy response and AMPK activation in PC-3 cells.Furthermore,TDZD8 (10μM) reduces mTOR phosphorylation levels at the S2448 site.In addition,TDZD8 (10μM) induces LKB1 nuclear-cytoplasm translocation.
体内研究	TDZD-8 (TDZD8,1 or 2mg/kg,i.p.) both reduces the induction of p-DARPP32 following chronic L-dopa treatment in parkinsonian animals.TDZD8 treatment of 21 days induces a significant reduction in PKA expression in rats with established dyskinesia.Moreover,TDZD8 reduces FosB mRNA level in the striatum and lowers the expression of PPEB mRNA to similar levels as in 6-OHDA-lesioned rats without treated with L-dopa.The decrease in dyskinesia induced by TDZD8 is overcome by dopamine rceptor-1 agonist.

推荐实验方法(仅供参考)

激酶实验：

GSK-3 activity is assayed in 50 mM Tris-HCl, pH 7.5,10mM MgCl2,1mM EGTA,and 1mM EDTA buffer,at 37℃,in the presence of 15μM GS-1 (substrate),15μM [γ-32P]ATP in a final volume of 12μL.After 20 min incubation at 37℃,4μL aliquots of the supernatant are spotted onto 2×2 cm pieces of Whatman P81 phosphocellulose paper, and 20s later,the filters are washed four times (for at least 10 min each time) in 1% phosphoric acid.The dried filters are transferred into scintillation vials,and the radioactivity is measured in a liquid scintillation counter.Blank values are subtracted,and the GSK-3β activity is expressed in picomoles of phosphate incorporated in GS-1 per 20 min or in percentage of maximal activity.

动物实验:

Apomorphine hydrochloride is administered (0.5mg/kg).L-dopa (25mg/kg) plus benserazide-HCl (6.25mg/kg) are given once-daily.TDZD8,a non-ATP competitive inhibitor of GSK-3β,is dissolved in 10% DMSO and is administered i.p.(TDZD8-L group,1mg/kg;TDZD8-H group,2mg/kg,respectively) 30 min prior to L-dopa intake for 3 weeks.(±)-1-Phenyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrochloride (SKF38393),a D1 Dopamine receptor agonist,is dissolved in saline and is administered i.p.(SKF38393-L group,5mg/kg;SKF38393-H group,10mg/kg,respectively) 30 min prior to L-dopa intake for 3 weeks.

保存条件：

2-8℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献